Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery
Authors:
- 6 February 2024
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (5) , 2902-2912
Abstract
Cancer antigen 19-9 (CA19-9) is widely used as a marker of pancreatic cancer tumor burden and response to therapy. Synthesis of CA19-9 and its circulatingKeywords
Funding Information
- Division of Cancer Prevention, National Cancer Institute (CA176828, CA210170, CA62924)
- Stand Up To Cancer (SU2C-AACR-DT25-17)
This publication has 35 references indexed in Scilit:
- Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic CancerAnnals of Surgery, 2020
- International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017Pancreatology, 2018
- Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2017
- Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotypingPancreatology, 2016
- FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitisJournal of Hepatology, 2013
- The prognostic and predictive value of serum CA19.9 in pancreatic cancerAnnals of Oncology, 2012
- A Natural History of FUT2 Polymorphism in HumansMolecular Biology and Evolution, 2009
- Smoking and serum CA19‐9 levels according to Lewis and secretor genotypesInternational Journal of Cancer, 2008
- Distribution of Lewis (FUT3) genotype and allele: frequencies in a biethnic United States populationAnnals of Hematology, 2002
- Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.1998